BELLUS Health Inc BLUSD

Primary Symbol: T.BLU

Healthcare Biotechnology

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

TSX:BLU - Post by User

BELLUS Health Inc

Bullboard Posts

Post by Time4TAon May 30, 2011 9:10am

287 Views

Post# 18643260

200 Day MA $0.11

Heavy Duty Bids showing up on Level II This AM Pre-Market....Interesting ! Looks set to Pick up .....Could the 200 DMA be in Focus this week ? Lows seems to have been put in last week. Confirmed by Daily and Weekly Chart.
121.5 Million Shares Have Traded @ Higher Levels in last few Months. A New Shareholder Base has definitely been established. BLU has Trended in Oversold Territory.....Appears a Change in Trend is in Process